Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1995-2002

  Pawlik, Cynthia A ^a   Houghton, Peter J ^a   Stewart, Clinton F ^a   Cheshire, Pamela J ^a   Richmond, Lois B ^a   Danks, Mary K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MEDULLOBLASTOMA; MICE; RHABDOMYOSARCOMA; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031824583     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation on 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
2. Friedman, H. S., Houghton, P. J., Schold, S. C., Keir, S., and Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 34: 171-174, 1994.
3. McCabe, F. L., and Johnson, R. K. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest., 12: 308-313, 1994.
4. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
5. Dennis, M. J., Beijnen, J. H., Grochow, L. B., and van Warmerdam, L. J. C. An overview of the clinical pharmacology of topotecan. Semin. Oncol., 24 (Suppl.): S512-S518, 1997.
6. Takimoto, C. H., and Arbuck, S. G. Clinical status and optimal use of topotecan. Oncology, 11: 1635-1646, 1997.
7. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Beil, B., Grier, H., and Vietti, T. J. Phase I trial and pharmacokinetic and pharmacodynamics study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J. Pediat. Hematol. Oncol., 18: 352-361, 1996.
8. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R. H., and Zeleniuch-Jacquotte, A. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a Phase I and pharmacokinetic study. Clin. Cancer Res., 3: 1245-1252, 1997.
9. Hsiang, Y-H., Herztberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
10. Hsiang, Y-H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
11. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
12. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
13. Uckun, F. M., Stewart, C. F., Reaman, G., Chelstrom, L. M., Jin, J., Chandan-Langlie, M., Waddick, K. G., White, J., and Evans, W. E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood, 85: 2817-2828, 1995.
14. Kapoor, R., Slade, D. L., Fujimori, A., Pommier, Y., and Harker, W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res., 7: 83-95, 1995.
15. Yang, C-H. J., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
16. Schneider, E., Horton, J. K., Yang, C-H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
17. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 56: 1664-1667, 1996.
18. Danks, M. K., Pawlik, C. A., Whipple, D. O., and Wolverton, J. S. Intermittent exposure of medulloblastoma cells to topotecan produces inhibition equivalent to continuous exposure. Clin. Cancer Res., 3: 1731-1738, 1997.
19. Saylors, R. L., III, Sidransky, D., Friedman, H. S., Bigner, S. H., Bigner, D. D., Vogelstein, B., and Brodeur, G. M. Infrequent p53 gene mutation in medulloblastomas. Cancer Res., 51: 4721-4723, 1991.
20. Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D. M., Webber, B. L., Houghton, P. J., Houghton, J. A., and Green, A. A. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet, 45: 148-155, 1987.
21. Stewart, C. F., Baker, S. D., Heideman, R. L., Jones, D., Crom, W. R., and Pratt, C. B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol., 12: 1946-1954, 1994.
22. Baker, S. D., Heideman, R. L., Crom, W. R., Kuttesch, J. F., Gajjar, A., and Stewart, C. F. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system rumors. Cancer Chemother. Pharmacol., 37: 195-202, 1996.
23. Beijnen, J. H., Smith, B. R., Keijer, W. J., van Gijn, R., ten Bokkel Huinink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
24. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide. Los Angeles, CA: USC Biomedical Simulations Resource, 1990.
25. Gibaldi, M., and Perrier, D. General derivation of the equation for time to reach a certain fraction of steady state. J. Pharm. Sci., 71: 474-475, 1982.
26. Underberg, W. J. M., Goossen, R. M. J., Smith, B. R., and Beijnen, J. H. Equilibrium kinetics of the new experimental tumour compound SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal., 8: 681-683, 1990.
27. Houghton, J. A., Houghton, P. J., and Webber, B. L. Growth and characterization of childhood rhabdomyosarcomas as xenografts. J. Natl. Cancer Inst. (Bethesda). 68: 437-443, 1982.
28. Zamboni, W. E., Santana, V., Gajjar, A. J., Meyer, W. H., Pappo, P. J., Houghton, P. J., and Stewart, C. F. Pharmacokinetically guided dose adjustment reduces variability in topotecan systemic exposure in children with solid tumors. Proc. Am. Soc. Clin. Oncol., 16: 205a, 1997.
29. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y., and Solary, E. The role of cell cycle regulations and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (Baltimore), 9: 1013-1024, 1995.
30. Holm, C., Convey, J., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of the DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
31. Jonsson, E., Fridborg, H., Csoka, S., Dhar, S., Sundstrom, C., Nygren, P., and Larsson, R. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br. J. Cancer, 76: 211-219, 1997.
32. O'Connor, P. M., Neives-Neira, W., Kerrigan, D., Bertrand, R., Goldman, J., Kohn, K. W., and Pommier, Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun., 3: 233-240, 1991.
33. 1 checkpoint does not increase cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
34. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
35. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
36. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier Y. G., Cheng, U-C., and Kaufmann, S. H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1674-1681, 1996.
37. Bharti, A. K., Olson, M. O., Kufe, D. W., and Rubin, E. H. Identification of a nucleolin binding site in human topoisomerase I. J. Biol. Chem., 271: 1993-1997, 1996.
38. Cao, C-X., Shao, R. G., and Pommier, Y. Phosphorylation of replication protein A induced by camptothecin is associated with activation of DNA-dependent protein kinase. Proc. Am. Assoc. Cancer Res., 39: 81, 1998.
39. Chen, A. Y., Okunieff, P., Pommier, Y., and Mitchell, J. B. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res., 57: 1529-1536, 1997.
40. Zamboni, W. C., Houghton, P. J., Thompson, J., Cheshire, P. J., Hanna, S. K., Richmond, L. B., Lou, X., and Stewart, C. F. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res., 4: 455-462, 1998.
41. Frei, E., III, Teicher, B. A., Holden, S. A., Cathcart, K. N., Wang, Y. Y., and Frei, E. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res., 48: 6417-6423, 1998.